Latest news with #Corvus
Yahoo
08-06-2025
- Science
- Yahoo
Space photo of the week: James Webb telescope peeks under the brim of a 'peculiar' Sombrero
When you buy through links on our articles, Future and its syndication partners may earn a commission. Quick facts What it is: The Sombrero Galaxy (M104), a peculiar galaxy Where it is: 30 million light-years distant between the Virgo and Corvus constellations When it was shared: June 3, 2025 Sequels are never as good as the originals, right? That certainly doesn't apply to the James Webb Space Telescope (JWST), whose latest image adds a new dimension of data to its spectacular 2024 image of the enigmatic Sombrero Galaxy. Galaxies are a mix of stars, gas and dust. How these three ingredients interact explains how galaxies evolve. However, to image all three ingredients requires shooting in different wavelengths of light. Cue JWST, which is able to collect longer, redder wavelengths of infrared light than optical telescopes like the Hubble Space Telescope. In December 2024, JWST shot the Sombrero in the mid-infrared for the first time, using its Mid-Infrared Instrument (MIRI) camera to reveal an elegant structure with a smooth inner disk. Related: 42 jaw-dropping James Webb Space Telescope images Now comes part two, this time using Webb's NIRCam (Near-Infrared Camera) instrument. The new data reveals light from stars that were previously blocked by dust. In this new image, the dust glows, revealing clouds of interstellar matter as well as red giant stars. While Webb's instruments pick up red giants in both the near-infrared and mid-infrared wavelengths — making them stand out clearly in the images — hotter blue stars emit light mostly in the visible and near-infrared spectrum, causing them to fade from view in Webb's images at longer wavelengths. MORE SPACE PHOTOS —Pink 'raindrops' on the sun captured in greatest detail ever —Violent galaxies seen 'jousting' near the dawn of time —Cotton candy clouds shine in one of Hubble's most beautiful images ever The galaxy also appears to have a warped inner disk and contain about 2,000 globular clusters — balls of ancient stars — in its halo. Since these clusters are chemically different from their galactic companions, it's probable that the Sombrero has a chaotic past, having merged with several smaller galaxies in its history. The new NIRCam data adds another layer of detail to a galaxy first documented 244 years ago. Originally observed in 1781 by the French astronomer Pierre Méchain, the Sombrero galaxy (also known as Messier 104 or M104) has long intrigued scientists due to its distinct, edge-on shape and luminous central bulge. Most galaxies' structures can be categorized as spiral, elliptical or irregular, but the Sombrero is classed as peculiar. For more sublime space images, check out our Space Photo of the Week archives.
Associated Press
04-06-2025
- Business
- Associated Press
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data includes 28-day follow up results for all patients in cohort 3 and continues to show earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, total daily dose 200 mg). Overall, data from cohorts 1-3 of the trial have demonstrated a favorable safety and efficacy profile, including a statistically significant improvement in Eczema Area and Severity Index (EASI) score for the soquelitinib treated patients compared to placebo at day 28 (p=0.036). 'The complete 28-day data from cohort 3 of our Phase 1 trial of soquelitinib in patients with atopic dermatitis is in-line with the data update we provided at the Society for Investigative Dermatology meeting last month,' said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. 'We are encouraged that results from cohort 3 continue to show earlier and deeper responses, along with a reduction in itch, which is an important factor for patients. We look forward to exploring the potential for further improvement in patient results with longer treatment duration that is being studied in our recently initiated extension cohort. Overall, the data to date is supportive of our view that ITK inhibition with soquelitinib has the potential to be a safe, effective and convenient new option for patients with atopic dermatitis and other immune diseases.' Dr. Miller will highlight the new interim data in a presentation at the Jefferies Global Healthcare Conference, which is scheduled for 9:20 am ET / 6:20 am PT on Thursday, June 5, 2025. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial As of May 28, 2025, enrollment in cohorts 1, 2 and 3 has been completed for a total of 48 patients and all patients (36 receiving soquelitinib and 12 placebos) had completed the 28-day treatment course. Patients in cohort 3 had more advanced disease with a higher mean baseline EASI score compared to patients in cohorts 1 and 2. At 28 days, the mean reduction in EASI for cohort 3 (n=12) was 64.8%, compared to 54.6% for cohort 1 and 2 combined (n=24) and 34.4% for placebo (n=12). The graphs below (Figures 1 and 2) show the kinetics of response for each of the cohorts and for the combined cohorts 1, 2 and 3. The placebo patients (n=4 per cohort, total n=12) are combined in both graphs. Separation of the curves for patients receiving active drug began at day 15 and increased by day 28 for cohorts 1 and 2. Cohort 3 patients experienced earlier and deeper separation from placebo starting by day 8. EASI scores continue to improve further in treated patients from all cohorts out to day 58. Figure 1: Percent Reduction in Mean EASI Score for Cohorts 1, 2 and 3 . Mean percent change in EASI score over time is shown. Treatment beginning is designated 'Baseline' and days post-baseline are shown. Screening to baseline data is shown and demonstrates relative disease stability. The study blinding remains in effect for the entire 58-day period. Numbers at the top of the graphs indicate numbers of patients evaluated at the various time points. Figure 2: Percent Reduction in Mean EASI Score for Combined Cohorts 1, 2 and 3. The data is displayed below with cohorts combined. Figure 3 below shows the percent of patients that achieved IGA (Investigator Global Assessment) 0 or 1 or EASI 75 at day 28 of treatment. The placebo patients from cohort 1 (n=4), cohort 2 (n=4) and cohort 3 (n=4) are combined, with no placebo patients achieving IGA 0 or 1 or EASI 75. IGA 0 or 1 and EASI 75 have been determined by the U.S. Food and Drug Administration (FDA) to be clinically meaningful and approvable endpoints and have been the endpoints used in clinical trials for other FDA approved treatments for atopic dermatitis. Four additional patients in cohort 3 are now included in the results as compared to the data reported at the Society for Investigative Dermatology (SID) annual meeting in May 2025 (SID data was as of May 6; these four patients had not yet completed the 28-day treatment course). One of the four patients achieved EASI 75 (this patient experienced an 89% reduction in EASI score) and IGA 1 at day 28 of treatment. Figure 3: Percent Patients Achieving Endpoints IGA 0 or 1, EASI 75 at Day 28 of Treatment Patient Reported Reductions in Itch Patients in the trial recorded the intensity of their pruritus, or itch, using the Peak Pruritus Numerical Rating Scale (PP-NRS), which rates the severity of itch on a scale from 0 (no itch) to 10 (the worst itch imaginable). A reduction of ≥4 points from baseline on the PP-NRS is considered to be a clinically meaningful result. In cohort 3, of the patients for whom adequate PP-NRS data was available, 4 of 8 (50%) had a ≥4 point reduction in PP-NRS score from baseline at day 28, with a reduction in itch seen as early as day 8. Of the remaining patients, two had baseline PP-NRS of less than 4 and two had incomplete PP-NRS data. 1 of 10 evaluable placebo patients (10%) experienced a ≥4 point reduction in PP-NRS score at Day 28. Safety Data As of May 28, 2025, no new safety signals have been observed. Soquelitinib was well tolerated, with no dose limiting toxicities (DLTs) and no clinically significant laboratory abnormalities observed in any of the cohorts. No interruption of drug dosing was seen in any of the cohorts. Grade 1/2 adverse events (treatment related and unrelated) were seen in 38.9% of patients receiving soquelitinib and 25% receiving placebo. Only one treatment related adverse event of grade 1 nausea was reported with soquelitinib treatment. Serum Cytokine and Other Biomarker Studies As reported previously, relationships between reductions in certain cytokines with improvement in EASI scores were observed. Reductions in serum cytokine levels were seen for IL-5, IL-9, IL-17, IL-31, IL-33, TSLP and TARC. Differences between responding and non-responding patients were found, while no such relationships were seen in the placebo group, and patients in cohort 3 had greater reductions in cytokines compared to cohorts 1 and 2. Increasing trends were seen in numbers of circulating T regulatory cells, consistent with the presumed mechanism of action of soquelitinib. Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Extension Cohort Corvus also announced that the first patient(s) has/have been enrolled in the recently announced extension cohort of the Phase 1 trial. This cohort is planned to enroll 24 patients randomized 1:1 between active and placebo, with patients in the treatment group receiving the same dose as cohort 3 – 200 mg orally twice per day. The treatment period for this group is 8 weeks, compared to 4 weeks in cohorts 1-3, with the same 30-day follow-up period with no treatment. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit or follow the Company on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements related to the potential of the Company's product candidates including soquelitinib and the potential for further improvement in patient results in the extension cohort of the Phase 1 trial of soquelitinib in patients with atopic dermatitis, the design and planned enrollment of the extension cohort, data in support of ITK inhibition with soquelitinib and its potential for patients, and continued advancement of the Company's clinical pipeline. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' 'seek,' 'will,' 'may' or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company's ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company's ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 [email protected] MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 [email protected] Figures accompanying this announcement are available at:
AsiaOne
31-05-2025
- General
- AsiaOne
In a first, NParks trials use of dead bird effigies to prevent crows from congregating, Singapore News
SINGAPORE - Hanging upside-down from a tree branch, the full-feathered "crow" was limp, its eyes devoid of any signs of life. The dead bird, however, is not real, but just a plastic effigy. It is part of an ongoing trial by the National Parks Board (NParks) to prevent murders of house crows (Corvus splendens), considered an invasive species here, from congregating in large groups. Such effigies have been tested overseas in places such as the US with some success, and NParks is testing them out here for the first time as a tool to disperse these birds. In response to queries from The Straits Times, Mr How Choon Beng, NParks' group director of wildlife management, said: "The effigies are placed at roost sites and positioned to resemble dead crows. The aim is to create a perception of danger and encourage the roosting crows to disperse to other locations." The realistic decoys were first deployed in Singapore in late 2023, with each effigy deployed at a site for about two weeks on average, NParks said. Since 2023, a total of 15 effigies have been put up across eight locations that are heavily populated with crows, or experience higher volumes of disturbances by crows. NParks shared that it received an average of nearly 7,000 cases of crow-related feedback annually from 2023 to 2024, relating to issues such as noise, sightings, attacks, feeding and soiling. The board did not reveal the exact locations of the set-ups, but The Straits Times had observed one effigy deployed on a tree outside Katong V mall in April. "This is a plastic crow. Please do not be alarmed," read a sign next to the tree where the effigy had been deployed. That effigy was taken down on April 24. As data collection is still ongoing, NParks said it was unable to provide further details. Trials of these crow effigies come after news of these birds flying at and pecking passers-by. Between February and March 2023, there were reports of crow attacks in Bishan and Serangoon, with some 10 passers-by getting hit or having crows swoop right by them in a 20-minute span near Block 110 Bishan Street 12. Another crow attack at Block 485B Tampines Avenue 9 in July 2024 led to the removal of 77 crow nests from a stretch of trees in Tampines. There were also cases of crows attacking humans outside Orchard Central mall in October 2024. Two birds attacked about 10 individuals in the span of an hour, ST observed, with one victim sustaining a bleeding earlobe. A 2008 scientific paper by the National Wildlife Research Centre of the US Department of Agriculture (USDA) Wildlife Services had cited an earlier paper that suggested that dead crows, when hung on fences or from trees near fields, "can be effective for months". That study had also suggested that "crows readily associate death and danger with places where their brethren have died". The USDA researchers then sought to test out their hypothesis that effigies could be an effective tool in dispersing crows. Each effigy was suspended upside down from a prominent branch near the top of a centrally located roost tree. Ahead of the winters of 2005 and 2006, the researchers installed effigies of dead crows in wooded areas of Lancaster in Pennsylvania, the US, where up to 40,000 crows would roost together. The first effigies were put up in November 2005, and by January of the following year, the crows had split into smaller roosting aggregations. Prior to the return of winter in October 2006, the researchers installed the effigies again, and observed that the area was used only sparingly by crows throughout the second winter. The researchers concluded that this tactic was effective in dispersing large numbers of crows at large roost sites away from the effigies. However, they also noted that crows are observant and wary of changes in their environment. Some crows occasionally returned to roost sites at night when the effigies were not as visible. House crows are common residents in cities and towns, and thrive in urban environments. In Singapore, these black birds can often be found at food centres and rubbish bins scavenging for leftover food. Their cawing and droppings can bring about inconvenience and unsanitary conditions when gathering and roosting, especially near residential areas. During the fledgling season between May and June, adult house crows get extra protective and may attack humans who come close to their young. The fledgling season is the period when young birds develop their ability to fly. Nature Society Singapore's bird group told ST previously that house crows pose a threat to local biodiversity as they are known to prey on the Malaysian plover, a critically endangered bird native to the Republic. Vice-president of research and conservation group Bird Society Singapore Movin Nyanasengeran noted that the practice of deploying crow effigies is common enough that one can buy such decoys easily online. "It will probably be effective, at least initially. Crows are, however, very intelligent, so it's tough to say if it will remain effective over time... but it is definitely preferable over shooting or poisoning the birds, and is unlikely to lead to any detrimental impacts on its welfare," added the PhD student, who studies bird species distributions at NUS. He added that it is difficult to predict when the crows would eventually learn that the decoys are harmless and do not indicate danger, before returning to roost. [[nid:709377]] The crow effigies add to a suite of measures already being implemented to manage crow populations in Singapore. These include removing nests and sources of food, modifying their habitats to make them less conducive for roosting and trapping the birds. "NParks adopts a holistic and science-based approach to managing pest bird species... (and) conducts studies to understand the ecology of the birds, such as their roosting patterns and movements," said NParks' Mr How. Those who wish to provide feedback on crows in their neighbourhoods can contact NParks' Animal and Veterinary Service on 1800-476-1600 or submit an online feedback form at How to control crow populations Avoid feeding crows. Under the Wildlife Act, offenders can be fined up to $5,000 for their first offence of feeding any wild animal, including crows, and up to $10,000 for subsequent offences. Mr How said NParks also monitors feedback on illegal bird feeding and undertakes active enforcement, which includes physical surveillance and the deployment of CCTV cameras at identified feeding hotspots. Fruits in trees planted in landed property should be harvested or covered with an opaque material. This is because crows are omnivores and feed on insects, fruits, vegetables, rubbish and carcasses. hose living in houses near hotspots where crows roost should remove water sources in their yards, as they may present a stable drinking source for the birds. Pet owners should remove unfinished food and spills if they feed their pets outdoors. Ideally, pets should be fed indoors. Residents of landed property can consider playing recordings of crow distress calls multiple times a day, or stringing up shiny metal pieces, such as CDs, to reflect sunlight and disperse roosting crows. However, this method may not be effective for long, as crows are intelligent birds. This article was first published in The Straits Times. Permission required for reproduction.
AsiaOne
31-05-2025
- General
- AsiaOne
In a first, NParks trials use of dead bird effigies to prevent crows from congregating
SINGAPORE - Hanging upside-down from a tree branch, the full-feathered "crow" was limp, its eyes devoid of any signs of life. The dead bird, however, is not real, but just a plastic effigy. It is part of an ongoing trial by the National Parks Board (NParks) to prevent murders of house crows (Corvus splendens), considered an invasive species here, from congregating in large groups. Such effigies have been tested overseas in places such as the US with some success, and NParks is testing them out here for the first time as a tool to disperse these birds. In response to queries from The Straits Times, Mr How Choon Beng, NParks' group director of wildlife management, said: "The effigies are placed at roost sites and positioned to resemble dead crows. The aim is to create a perception of danger and encourage the roosting crows to disperse to other locations." The realistic decoys were first deployed in Singapore in late 2023, with each effigy deployed at a site for about two weeks on average, NParks said. Since 2023, a total of 15 effigies have been put up across eight locations that are heavily populated with crows, or experience higher volumes of disturbances by crows. NParks shared that it received an average of nearly 7,000 cases of crow-related feedback annually from 2023 to 2024, relating to issues such as noise, sightings, attacks, feeding and soiling. The board did not reveal the exact locations of the set-ups, but The Straits Times had observed one effigy deployed on a tree outside Katong V mall in April. "This is a plastic crow. Please do not be alarmed," read a sign next to the tree where the effigy had been deployed. That effigy was taken down on April 24. As data collection is still ongoing, NParks said it was unable to provide further details. Trials of these crow effigies come after news of these birds flying at and pecking passers-by. Between February and March 2023, there were reports of crow attacks in Bishan and Serangoon, with some 10 passers-by getting hit or having crows swoop right by them in a 20-minute span near Block 110 Bishan Street 12. Another crow attack at Block 485B Tampines Avenue 9 in July 2024 led to the removal of 77 crow nests from a stretch of trees in Tampines. There were also cases of crows attacking humans outside Orchard Central mall in October 2024. Two birds attacked about 10 individuals in the span of an hour, ST observed, with one victim sustaining a bleeding earlobe. A 2008 scientific paper by the National Wildlife Research Centre of the US Department of Agriculture (USDA) Wildlife Services had cited an earlier paper that suggested that dead crows, when hung on fences or from trees near fields, "can be effective for months". That study had also suggested that "crows readily associate death and danger with places where their brethren have died". The USDA researchers then sought to test out their hypothesis that effigies could be an effective tool in dispersing crows. Each effigy was suspended upside down from a prominent branch near the top of a centrally located roost tree. Ahead of the winters of 2005 and 2006, the researchers installed effigies of dead crows in wooded areas of Lancaster in Pennsylvania, the US, where up to 40,000 crows would roost together. The first effigies were put up in November 2005, and by January of the following year, the crows had split into smaller roosting aggregations. Prior to the return of winter in October 2006, the researchers installed the effigies again, and observed that the area was used only sparingly by crows throughout the second winter. The researchers concluded that this tactic was effective in dispersing large numbers of crows at large roost sites away from the effigies. However, they also noted that crows are observant and wary of changes in their environment. Some crows occasionally returned to roost sites at night when the effigies were not as visible. House crows are common residents in cities and towns, and thrive in urban environments. In Singapore, these black birds can often be found at food centres and rubbish bins scavenging for leftover food. Their cawing and droppings can bring about inconvenience and unsanitary conditions when gathering and roosting, especially near residential areas. During the fledgling season between May and June, adult house crows get extra protective and may attack humans who come close to their young. The fledgling season is the period when young birds develop their ability to fly. Nature Society Singapore's bird group told ST previously that house crows pose a threat to local biodiversity as they are known to prey on the Malaysian plover, a critically endangered bird native to the Republic. Vice-president of research and conservation group Bird Society Singapore Movin Nyanasengeran noted that the practice of deploying crow effigies is common enough that one can buy such decoys easily online. "It will probably be effective, at least initially. Crows are, however, very intelligent, so it's tough to say if it will remain effective over time... but it is definitely preferable over shooting or poisoning the birds, and is unlikely to lead to any detrimental impacts on its welfare," added the PhD student, who studies bird species distributions at NUS. He added that it is difficult to predict when the crows would eventually learn that the decoys are harmless and do not indicate danger, before returning to roost. [[nid:709377]] The crow effigies add to a suite of measures already being implemented to manage crow populations in Singapore. These include removing nests and sources of food, modifying their habitats to make them less conducive for roosting and trapping the birds. "NParks adopts a holistic and science-based approach to managing pest bird species... (and) conducts studies to understand the ecology of the birds, such as their roosting patterns and movements," said NParks' Mr How. Those who wish to provide feedback on crows in their neighbourhoods can contact NParks' Animal and Veterinary Service on 1800-476-1600 or submit an online feedback form at How to control crow populations Avoid feeding crows. Under the Wildlife Act, offenders can be fined up to $5,000 for their first offence of feeding any wild animal, including crows, and up to $10,000 for subsequent offences. Mr How said NParks also monitors feedback on illegal bird feeding and undertakes active enforcement, which includes physical surveillance and the deployment of CCTV cameras at identified feeding hotspots. Fruits in trees planted in landed property should be harvested or covered with an opaque material. This is because crows are omnivores and feed on insects, fruits, vegetables, rubbish and carcasses. hose living in houses near hotspots where crows roost should remove water sources in their yards, as they may present a stable drinking source for the birds. Pet owners should remove unfinished food and spills if they feed their pets outdoors. Ideally, pets should be fed indoors. Residents of landed property can consider playing recordings of crow distress calls multiple times a day, or stringing up shiny metal pieces, such as CDs, to reflect sunlight and disperse roosting crows. However, this method may not be effective for long, as crows are intelligent birds. This article was first published in The Straits Times. Permission required for reproduction.
Yahoo
28-05-2025
- Business
- Yahoo
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit or follow the Company on LinkedIn. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@ MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
